Background and purpose: This study calculated the effects on serum chloride (Cl) levels, after treatment with either of 2 drugs: the erythropoietin (Epo) and the antioxidant lazaroid ...
Background and purpose: This study calculated the effects on serum chloride (Cl) levels, after treatment with either of 2 drugs: the erythropoietin (Epo) and the antioxidant lazaroid (L) drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the certain influence, after the respective drug usage in induced ischemia-reperfusion (IR) animal experiment.
Materials and Methods: The 2 main experimental endpoints at which the serum Cl levels were evaluated was the 60th reperfusion min (for the groups A, C, and E) and the 120th reperfusion min (for the groups B, D, and F). Especially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after the L administration.
Results: The first preliminary study of Epo presented a non-significant hypochloremic effect by 0.74%+0.55% (p-value=0.1701). However, the second preliminary study of U-74389G showed a significant hypochloremic effect by 0.75%+0.34% (p-value=0.0310). These two studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that L is 1.012762-fold [1.011746 - 1.01378] more hypochloremic than Epo (p-value=0.0000).
Conclusion: The antioxidant capacities of U-74389G ascribe 1.012762-fold more hypochloremic effects than Epo (p-value=0.0000).